Oxidative phosphorylation inducers fight pathological angiogenesis.
Angiogenesis Inhibitors
/ pharmacology
Animals
Humans
Mitochondrial Diseases
/ drug therapy
Neoplasms
/ drug therapy
Neovascularization, Pathologic
/ drug therapy
Retinal Diseases
/ drug therapy
Retrospective Studies
Rheumatic Diseases
/ drug therapy
Vascular Endothelial Growth Factor A
/ metabolism
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
21
01
2019
revised:
04
03
2019
accepted:
11
03
2019
pubmed:
19
3
2019
medline:
17
6
2020
entrez:
19
3
2019
Statut:
ppublish
Résumé
Pathological mutations in subunits of the oxidative phosphorylation (OXPHOS) system, or inhibitors of this biochemical pathway, increase the production of vascular endothelial growth factor (VEGF) and pathological angiogenesis. In many angiogenesis-related diseases, such as retinal, rheumatoid diseases, or cancer, OXPHOS dysfunction can be found. Thus, enhancing OXPHOS might be a promising therapeutic approach for pathologic angiogenesis.
Identifiants
pubmed: 30880173
pii: S1359-6446(19)30035-2
doi: 10.1016/j.drudis.2019.03.014
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1731-1734Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.